PINK:NGENF
NervGen Pharma Corp. Stock News
$1.69
-0.0300 (-1.74%)
At Close: Jun 14, 2024
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
08:30am, Friday, 17'th May 2024
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the t
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
08:30am, Thursday, 16'th May 2024
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participant
NervGen Files Management Information Circular and Announces Board of Directors Transition
08:30am, Tuesday, 07'th May 2024
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver,
NervGen Engages Russo Partners LLC to Provide Public Relations Services
08:30am, Thursday, 25'th Apr 2024
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
09:00am, Wednesday, 17'th Apr 2024
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway throug
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
08:00am, Wednesday, 21'st Feb 2024
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma Grants Stock Options
05:37pm, Tuesday, 20'th Feb 2024
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
08:47am, Thursday, 15'th Feb 2024
On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make NVG-291 available to placebo-treated subjects following
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
08:30am, Thursday, 09'th Nov 2023
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, British Columbia--(Newsfile Corp. - November
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
08:30am, Monday, 23'rd Oct 2023
Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected
NervGen Pharma Appoints John Ruffolo to Board of Directors
08:00am, Tuesday, 17'th Oct 2023
Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen's board Important board
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
08:30am, Monday, 25'th Sep 2023
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - September 25,
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
08:30am, Monday, 11'th Sep 2023
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to devel
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for